Swedish fund finances studies for biopharmaceutical park in Kenya
By the AFREEQUE newsroom, based on Tuko

Apifa Biotech has secured funding from Swedfund, Sweden’s development finance institution, for preparatory studies for a biopharmaceutical park at Konza Technopolis in Kenya. The first hub, dedicated to pharmaceutical manufacturing, aims to reduce dependence on imported medicines, Tuko reports.
Kenya is set to host its first hub dedicated to pharmaceutical manufacturing and life sciences. Apifa Biotech has secured funding from Swedfund, Sweden’s development finance institution, to carry out preparatory studies for a planned biopharmaceutical park at Konza Technopolis. The announcement was made on 12 November, according to Tuko, and the aim is to reduce the country’s dependence on imported medicines.
The project is based on a public-private partnership between Apifa Biotech and the Technopolis Development Authority, the body responsible for Konza Technopolis. The National Treasury approved it in April 2026 to proceed to the development phase. A consortium comprising two global groups, JLL (Jones Lang LaSalle, a real estate and investment consultancy) and IQVIA (a healthcare research data analytics company), was selected to conduct the feasibility study.
Swedfund’s funding is intended to establish the project’s technical and commercial viability in order to attract long-term private investment at a later stage. Elsa Ekblom, head of the health sector at Swedfund’s Project Accelerator programme, stressed that the funding should advance the preparatory work. John Paul Okwiri, chief executive of the Technopolis Development Authority, believes the park will make Konza a pharmaceutical hub.



